Statistics from Altmetric.com
General cardiology, heart failure
Ramipril improves symptoms of intermittent claudication
Approximately a third of patients with peripheral arterial disease (PAD) will develop intermittent claudication. A previous pilot trial found that the angiotensin-converting enzyme inhibitor ramipril is associated with increased pain-free and maximum walking times, contrasting with previous ACE inhibitor studies which may have been limited by issues of small sample size, short intervention duration, and lack of a placebo group. Therefore this trial was designed to investigate the effect of 24 weeks of ramipril therapy on walking distance and health-related quality of life as compared with placebo in a larger, more general PAD population including patients with diabetes and patients with aortoiliac and infrainguinal disease.
212 patients with PAD were recruited from three Australian hospitals, and randomised to receive 10 mg of ramipril daily, or placebo, for 24 weeks. Maximum and pain-free walking times were recorded during a standard treadmill test. The Walking Impairment Questionnaire (WIQ) and Short-Form 36 Health Survey (SF-36) were used to assess walking ability and quality of life, respectively.
At six months, patients taking ramipril had a 75-s increase in pain-free walking time compared to those taking placebo (p<0.001), and a 255-s increase in maximum walking time (p<0.001). WIQ and SF-36 scores also improved, although ramipril did …